Register for our free email digests:
Latest From Stada Arzneimittel AG
IPOs are up, hemophilia is driving company pipelines, speculation over Pascal Soriot's career plans drive billions from AstraZeneca's market capitalization, Sanofi signs a $650m vaccine deal, private equity bidders up their offer for Stada and earnings season kicks off. Commercial capsule rounds up recent business news and trends reported by sister publication Scrip.
Analyst speculates that Gilead could move to acquire Spring Bank if combo trial yields promising data for functional cure of hepatitis B. Eisai in-licenses PARP inhibitor with potential in breast cancer from Oncology Venture, while Sunovion out-licenses three corticosteroid products to Covis.
Servier and Transgene will collaborate to apply viral vector technology to the development of CAR-T therapeutics, while Chinese vaccine maker Sinovac is taken private by an investment consortium.
Stada's top brass have quit following rumors earlier this week of a fresh takeover bid for the generic company from equity groups Bain and Cinven; ex-Boehringer executive Tjeenk Willink has been named incoming CEO.
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Laboratory Testing Services
- Anatomical Pathology
- Therapeutic Areas
- Gynecological, Urological
- North America
- Parent & Subsidiaries
- Pathology Inc.
- Senior Management
Vicki DiFrancesco, Pres. & CEO
Steve Pierce, CFO
Alfred Lui, MD, Chmn. & CMO
Ron Blum, SVP, Mktg. & Strategic Bus. Dev.
Michael D Mosunic, VP, Sales
- Contact Info
Phone: (310) 769-0561
19951 Mariner Ave.
Torrance, CA 90503
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.